TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17972377

Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter-Defibrillator (ICD) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICD therapy for primary prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICD therapy for secondary prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 15814547

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.2 mg/kg/day p.o.)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cyclosporin-ME (7 mg/kg/day p.o.)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cyclosporin-ME
Number of subjects: 205
Study: 11823896

Group type: EXPERIMENTAL
Intervention: Chromium treatment (400 microg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chromium treatment
Number of subjects: 0
Study: 12666956

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste (Meridol)
Number of subjects: 103

Group type: COMPARATOR
Intervention: NaF toothpaste (control)
Number of subjects: 103
Study: 7801960

Group type: EXPERIMENTAL
Intervention: Case histories identifying the patient's race as black
Number of subjects: 197

Group type: COMPARATOR
Intervention: Case histories identifying the patient's race as white
Number of subjects: 197
Study: 2150170

Group type: EXPERIMENTAL
Intervention: Chelon glass ionomer cement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketac-Fil glass ionomer cement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional composite resin
Number of subjects: 0
Study: 361057

Group type: EXPERIMENTAL
Intervention: Fenoprofen 200 mg and Paracetamol 500 mg (combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenoprofen 200 mg (separate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol 500 mg (separate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31931678

Group type: EXPERIMENTAL
Intervention: Wealth simple-categorization dominant (observer perspective)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age simple-categorization dominant (actor perspective)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wealth simple-categorization dominant (actor perspective)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple-categorization dominance (Study 2)
Number of subjects: 0
Study: 30701554

Group type: EXPERIMENTAL
Intervention: 3 g of green cardamom for 10 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Rusk powder (placebo) for 10 weeks
Number of subjects: 83
Study: 29021123

Group type: EXPERIMENTAL
Intervention: RBCs stored longer than 35 days
Number of subjects: 24736

Group type: COMPARATOR
Intervention: RBCs stored no longer than 7 days
Number of subjects: 24736

Group type: EXPERIMENTAL
Intervention: RBCs stored 8-35 days
Number of subjects: 24736
Study: 25439709

Group type: EXPERIMENTAL
Intervention: Mirror therapy supported by telerehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional mirror therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 23823745

Group type: EXPERIMENTAL
Intervention: Homeopathic prophylaxis at drying off
Number of subjects: 24
Study: 21565823

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program delivered by a public health department
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Diabetes education and risk screening
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Study recruitment process
Number of subjects: 544
Study: 19628486

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention (30 min continuous moderate intensity cycle ergometry, twice weekly for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 30
Study: 16758177

Group type: EXPERIMENTAL
Intervention: Walking activity (measured by total heart beat index - THBI)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Walking performance (measured by gait velocity and average daily strides)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Maximum peak pressure over the affected foot
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Maximum peak pressure over the contralateral side
Number of subjects: 23
Study: 15356039

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12381221

Group type: EXPERIMENTAL
Intervention: Biapenem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 0
Study: 9646891

Group type: EXPERIMENTAL
Intervention: Nicotine (administered via dermal patch)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 6
Study: 7923540

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-diabetic patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diabetic patients with degenerative complications
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-diabetic patients with degenerative complications
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Drug prescriptions for diabetic patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Drug prescriptions for non-diabetic patients
Number of subjects: 100
Study: 2800576

Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg plus diazepam 10 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Butorphanol/diazepam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (Thiopental)
Number of subjects: 100
Study: 337758

Group type: EXPERIMENTAL
Intervention: Amipaque 290 mg I/ml
Number of subjects: 30

Group type: COMPARATOR
Intervention: Urografin 60% (292 mg I/ml)
Number of subjects: 30
Study: 30917673

Group type: EXPERIMENTAL
Intervention: Appearance-framed message
Number of subjects: 104227

Group type: COMPARATOR
Intervention: Health-framed message
Number of subjects: 104227
Study: 27335145

Group type: EXPERIMENTAL
Intervention: Topical rose oil (in the carrier of almond oil)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (carrier oil)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 120
Study: 26054452

Group type: EXPERIMENTAL
Intervention: Treatment as usual and hypnosis (TAU+HYP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 102
Study: 23241726

Group type: EXPERIMENTAL
Intervention: 0.6 µg·kg·min remifentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.9 µg·kg·min remifentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.3 µg·kg·min remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 21880278

Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined oral contraceptive pills (OC)
Number of subjects: 0
Study: 19604194

Group type: EXPERIMENTAL
Intervention: Manual in-line stabilisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No manual in-line stabilisation
Number of subjects: 0
Study: 16636217

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg subcutaneously once a week for 4 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15257811

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17-HPC) administered intramuscularly (341 mg every 3 days)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Intra-vaginal progesterone (90 mg daily)
Number of subjects: 320
Study: 11169254

Group type: EXPERIMENTAL
Intervention: HLA-G*01011 allele
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: HLA-G*01012 allele
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: HLA-G*01013 allele
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: HLA-G*0105N allele
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: HLA-G*01041 allele
Number of subjects: 94
Study: 9484876

Group type: EXPERIMENTAL
Intervention: grepafloxacin, 600 mg od
Number of subjects: 264

Group type: COMPARATOR
Intervention: amoxycillin, 500 mg tds
Number of subjects: 264
Study: 29097056

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus community-based bionic leg training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 0
Study: 27566671

Group type: EXPERIMENTAL
Intervention: HFR-S
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: HFR
Number of subjects: 41

Group type: COMPARATOR
Intervention: ol-HDF
Number of subjects: 41
Study: 25953472

Group type: EXPERIMENTAL
Intervention: Acrysof SA60AT (interrupted optic edge) IOL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tecnis ZCB00 (continuous optic edge) IOL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 50
Study: 23257680

Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone dipropionate (nBDP) 800 µg, administered twice daily for 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone dipropionate (nBDP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19650848

Group type: EXPERIMENTAL
Intervention: MHRV (mechanical heat recovery ventilation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 120
Study: 17684134

Group type: EXPERIMENTAL
Intervention: Combination botanical supplement (Curcuma longa, Cynara scolymus, Rosmarinus officinalis, Schisandra chinensis, Silybum marinum, and Taraxacum officinalis; n = 15)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dietary changes (3 servings/d crucifers or dark leafy greens, 30 g/d fiber, 1‐2 liters/d water, and limiting caffeine and alcohol consumption to 1 serving each/wk; n = 10)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 40
Study: 14605834

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional hemorrhoidectomy
Number of subjects: 100
Study: 11800416

Group type: EXPERIMENTAL
Intervention: Quinapril (10-20 mg per day)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 253
Study: 11038811

Group type: EXPERIMENTAL
Intervention: Colposuspension
Number of subjects: 95

Group type: COMPARATOR
Intervention: Kelly operation
Number of subjects: 95
Study: 7977602

Group type: EXPERIMENTAL
Intervention: Higher plasma fibrinogen levels
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: History of glaucoma
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Higher fibrinogen level (in women)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Estrogen use (in women)
Number of subjects: 198
Study: 2659634

Group type: EXPERIMENTAL
Intervention: Occlusin restorations
Number of subjects: 447

Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 447
Study: 791381

Group type: EXPERIMENTAL
Intervention: Jacobson-Wolpe autogenic-relaxation training
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EMG relaxation training
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EMG relaxation training combined with Jacobson-Wolpe autogenic instructions
Number of subjects: 18

Group type: COMPARATOR
Intervention: Verbal relaxation instructions
Number of subjects: 18
Study: 30375309

Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 5212
Study: 27707640

Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Burn Cool Spray®
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Burnshield®
Number of subjects: 96
Study: 26332930

Group type: EXPERIMENTAL
Intervention: Behavioral family weight management intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 93
Study: 24490063

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional haemostasis (CH)
Number of subjects: 61
Study: 21575819

Group type: EXPERIMENTAL
Intervention: Higher scores on hostility
Number of subjects: 1771

Group type: EXPERIMENTAL
Intervention: Higher scores on depressive symptoms
Number of subjects: 1771

Group type: EXPERIMENTAL
Intervention: Being bully-victims
Number of subjects: 1771
Study: 19649375

Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions for weight gain management
Number of subjects: 0
Study: 17374659

Group type: EXPERIMENTAL
Intervention: High linoleic acid (LA) diet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low linoleic acid (LA) diet
Number of subjects: 22
Study: 15125626

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Expectant management (successful spontaneous loss)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Managed according to own choice (Expectant)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Managed according to own choice (Surgical)
Number of subjects: 136
Study: 11519628

Group type: EXPERIMENTAL
Intervention: Therapeutic Workplace
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 40
Study: 9282426

Group type: EXPERIMENTAL
Intervention: Anastrozole (Arimidex‐Zeneca)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole (Femara‐Novartis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 0
Study: 7946232

Group type: EXPERIMENTAL
Intervention: Open-door policy combined with a structured activity programme (experimental group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not permitted to leave the ward, no participation in activities)
Number of subjects: 50
Study: 3284421

Group type: EXPERIMENTAL
Intervention: 0.15 mg clonidine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.4 mg adrenaline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.2 mg adrenaline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vasoconstrictors (0.15 mg clonidine or 0.4 mg adrenaline)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 80
Study: 31560783

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study: 27541270

Group type: EXPERIMENTAL
Intervention: Immediate ibuprofen (IIBU)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Delayed ibuprofen (DIBU)
Number of subjects: 850

Group type: COMPARATOR
Intervention: No ibuprofen (NIBU)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Paracetamol (IPARA)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Delayed paracetamol (DPARA)
Number of subjects: 850

Group type: COMPARATOR
Intervention: No paracetamol (NPARA)
Number of subjects: 850
Study: 25596571

Group type: EXPERIMENTAL
Intervention: Brucella infection (patient group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (30 healthy individuals)
Number of subjects: 24
Study: 23275387

Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily for 2 years (P-group)
Number of subjects: 225

Group type: COMPARATOR
Intervention: No prednisolone (NoP-group)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily (P-group)
Number of subjects: 225
Study: 22147238

Group type: EXPERIMENTAL
Intervention: Commercially available dentifrice with added mineral oil (Nujol®) for group 2 (G2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Commercially available dentifrice with added vegetable oil (Alpha Care®) for group 3 (G3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Commercially available dentifrice (control group 1 - G1)
Number of subjects: 30
Study: 19028705

Group type: EXPERIMENTAL
Intervention: Oral nicotinamide (1500 or 500 mg daily for 1 week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (administered for 1 week)
Number of subjects: 0
Study: 17258215

Group type: EXPERIMENTAL
Intervention: Laparoscopy with instillation of human endometrioma material, no lavage
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Laparoscopy with instillation of human endometrioma material, followed by clearance of all visible endometrioma fluid by saline lavage and suction
Number of subjects: 24

Group type: COMPARATOR
Intervention: Laparoscopy alone
Number of subjects: 24
Study: 15168386

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 11470690

Group type: EXPERIMENTAL
Intervention: Moderate nuclear opacities
Number of subjects: 4477

Group type: EXPERIMENTAL
Intervention: Moderate cortical opacities
Number of subjects: 4477
Study: 9923984

Group type: EXPERIMENTAL
Intervention: Homeopathic preparation 'Tinnitus' (D60 potency)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7828257

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.1 mg.ml‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3056209

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intramuscular papaveretum
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 114
Study: 31406237

Group type: EXPERIMENTAL
Intervention: Desloratadine treatment
Number of subjects: 114
Study: 29975623

Group type: EXPERIMENTAL
Intervention: IFRT plus six cycles of cyclophosphamide, vincristine, and prednisolone (CVP) or R-CVP (with rituximab)
Number of subjects: 150

Group type: COMPARATOR
Intervention: IFRT alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: R-CVP (with rituximab)
Number of subjects: 150
Study: 26606887

Group type: EXPERIMENTAL
Intervention: Low SSB (≤1 SSB serv/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: High SSB (≥2 serv/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Medium SSB (>1 - <2 serv/day)
Number of subjects: 47
Study: 24242902

Group type: EXPERIMENTAL
Intervention: EMD 525797 (DI17E6) 35, 100, 250, 500, 1000, or 1500 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: EMD 525797 (DI17E6)
Number of subjects: 55
Study: 22042368

Group type: EXPERIMENTAL
Intervention: Adjuvant aromatase inhibitor therapy
Number of subjects: 415
Study: 21135341

Group type: EXPERIMENTAL
Intervention: Dual-method protection use
Number of subjects: 701

Group type: COMPARATOR
Intervention: Dual-method protection users
Number of subjects: 701
Study: 17693918

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus strain GG (Culturelle, ConAgra Foods, Omaha, NE)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo capsule of insulin
Number of subjects: 61
Study: 15834298

Group type: EXPERIMENTAL
Intervention: COER-verapamil
Number of subjects: 16602

Group type: COMPARATOR
Intervention: Atenolol or hydrochlorothiazide (investigator's choice)
Number of subjects: 16602
Study: 12042429

Group type: EXPERIMENTAL
Intervention: Barley bread containing lactic acid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference barley bread (without lactic acid)
Number of subjects: 10
Study: 10223935

Group type: EXPERIMENTAL
Intervention: Penciclovir (PCV) 5 mg/kg every 12 hours (q12h)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Penciclovir (PCV) 5 mg/kg every 8 hours (q8h)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Acyclovir (ACV) 5 mg/kg every 8 hours (q8h)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Penciclovir (PCV) q12h vs Acyclovir (ACV) q8h
Number of subjects: 342

Group type: COMPARATOR
Intervention: Penciclovir (PCV) q8h vs Acyclovir (ACV) q8h
Number of subjects: 342

Group type: COMPARATOR
Intervention: Penciclovir (PCV) q12h or q8h vs Acyclovir (ACV) q8h
Number of subjects: 342
Study: 10150324

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (1 g + 0.5 g)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cefazolin (0.5 g)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cefoxitin (1 g)
Number of subjects: 58
Study: 2142172

Group type: EXPERIMENTAL
Intervention: 10% triethanolamine application
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aqueous cream
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both treatments (triethanolamine and aqueous cream)
Number of subjects: 20
Study: 368364

Group type: EXPERIMENTAL
Intervention: Cephalosporin therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 31113338

Group type: COMPARATOR
Intervention: Substantial Clinical Improvement (SCI) at d0 (30% improvement in NIHSS)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Substantial Clinical Improvement (SCI) at d1 (40% improvement in NIHSS)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Substantial Clinical Improvement (SCI) at d7 (70% improvement in NIHSS)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Successful reperfusion
Number of subjects: 423

Group type: COMPARATOR
Intervention: Shorter time to treatment
Number of subjects: 423
Study: 29117152

Group type: EXPERIMENTAL
Intervention: Proposed mobile data gathering scheme using Metropolis-Hastings algorithm with delayed acceptance and Kronecker compressive sensing (KCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed mobile data gathering scheme
Number of subjects: 0
Study: 25721698

Group type: EXPERIMENTAL
Intervention: 100 μg vitamin D3 daily
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: 50 μg vitamin D3 daily
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 23874597

Group type: EXPERIMENTAL
Intervention: Enhanced community‐based voluntary counseling and testing
Number of subjects: 50000

Group type: COMPARATOR
Intervention: Control communities (not explicitly defined in the abstract)
Number of subjects: 50000
Study: 20807322

Group type: EXPERIMENTAL
Intervention: 10 mg on-demand vardenafil ODT
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study: 19491798

Group type: EXPERIMENTAL
Intervention: Sinupret in age-adjusted doses
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no Sinupret)
Number of subjects: 40
Study: 17261211

Group type: COMPARATOR
Intervention: Saline (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ondansetron 150 microg kg‐1 intravenously at dural closure (Group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Two doses of Ondansetron 150 microg kg‐1 intravenously, second dose after 6 h (Group 3)
Number of subjects: 90